Wegeners granulomatosis secondary prevention

Jump to navigation Jump to search

Granulomatosis with polyangiitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Granulomatosis with polyangiitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Wegeners granulomatosis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Wegeners granulomatosis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wegeners granulomatosis secondary prevention

CDC on Wegeners granulomatosis secondary prevention

Wegeners granulomatosis secondary prevention in the news

Blogs on Wegeners granulomatosis secondary prevention

Directions to Hospitals Treating Granulomatosis with polyangiitis

Risk calculators and risk factors for Wegeners granulomatosis secondary prevention

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Secondary Prevention

General well-being and laboratory organ markers are checked on a regular basis to ascertain the patient has remained in remission.

References

Template:WikiDoc Sources